Humacyte, Inc.
HUMA
$2.53
$0.135.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -26.80% | 2.36% | 23.58% | 51.88% | 23.07% |
| Gross Profit | 29.23% | -2.36% | -23.58% | -51.88% | -23.07% |
| SG&A Expenses | 53.11% | 23.83% | 20.38% | 86.32% | 1.53% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.82% | 7.28% | 22.79% | 24.87% | 18.06% |
| Operating Income | 12.77% | -7.28% | -22.79% | -24.87% | -18.06% |
| Income Before Tax | 222.71% | 16.59% | -50.81% | -149.55% | 13.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 222.71% | 16.59% | -50.81% | -149.55% | 13.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 222.71% | 16.59% | -50.81% | -149.55% | 13.72% |
| EBIT | 12.77% | -7.28% | -22.79% | -24.87% | -18.06% |
| EBITDA | 13.86% | -7.93% | -24.70% | -28.09% | -21.27% |
| EPS Basic | 194.88% | 31.94% | -30.64% | -116.43% | 17.68% |
| Normalized Basic EPS | 68.08% | 19.12% | -7.13% | -12.79% | -14.29% |
| EPS Diluted | 194.88% | 31.94% | -30.64% | -116.43% | 17.68% |
| Normalized Diluted EPS | 68.15% | 19.12% | -7.13% | -12.79% | -14.29% |
| Average Basic Shares Outstanding | 21.48% | 22.56% | 15.43% | 15.30% | 4.83% |
| Average Diluted Shares Outstanding | 21.72% | 22.56% | 15.43% | 15.30% | 4.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |